Table 4

Plasma levels of coagulation factors and inhibitors

FII, percentageFV, percentageTotal PS, percentageFree PS, percentageFree TFPI, ng/mL
Controls 92.0 ± 14.7 94.9 ± 19.3 98.7 ± 16.6 89.8 ± 13.3 9.5 ± 3.1 
ET 91.5 ± 17.4 85.3 ± 23.9* 96.6 ± 19.6 83.6 ± 14.8* 11.1 ± 4.0 
    Negative (n = 29) 95.0 ± 18.5 91.3 ± 26.0 101.0 ± 20 88.8 ± 15.5 11.5 ± 4.3 
    Heterozygous (n = 30) 87.8 ± 15.6 79.0 ± 19† 92.1 ± 18.5* 78.6 ± 11.5† 10.7 ± 3.9 
PV 82.7 ± 15† 73.4 ± 21.1† 85.9 ± 16† 73.0 ± 13.8† 10.0 ± 2.3 
    Negative (n = 3) 100 ± 23 80 ± 22 87.0 ± 11 75.1 ± 13 9.03 ± 2.8 
    Heterozygous (n = 17) 83 ± 12* 80 ± 24† 88.4 ± 17* 74.5 ± 16† 11.03 ± 2.8 
    Homozygous (n = 10) 78 ± 14† 63 ± 14† 83.1 ± 15† 73.8 ± 10† 8.83 ± 0.78 
FII, percentageFV, percentageTotal PS, percentageFree PS, percentageFree TFPI, ng/mL
Controls 92.0 ± 14.7 94.9 ± 19.3 98.7 ± 16.6 89.8 ± 13.3 9.5 ± 3.1 
ET 91.5 ± 17.4 85.3 ± 23.9* 96.6 ± 19.6 83.6 ± 14.8* 11.1 ± 4.0 
    Negative (n = 29) 95.0 ± 18.5 91.3 ± 26.0 101.0 ± 20 88.8 ± 15.5 11.5 ± 4.3 
    Heterozygous (n = 30) 87.8 ± 15.6 79.0 ± 19† 92.1 ± 18.5* 78.6 ± 11.5† 10.7 ± 3.9 
PV 82.7 ± 15† 73.4 ± 21.1† 85.9 ± 16† 73.0 ± 13.8† 10.0 ± 2.3 
    Negative (n = 3) 100 ± 23 80 ± 22 87.0 ± 11 75.1 ± 13 9.03 ± 2.8 
    Heterozygous (n = 17) 83 ± 12* 80 ± 24† 88.4 ± 17* 74.5 ± 16† 11.03 ± 2.8 
    Homozygous (n = 10) 78 ± 14† 63 ± 14† 83.1 ± 15† 73.8 ± 10† 8.83 ± 0.78 

Data (mean ± SD) are reported according to disease type (ET or PV) and to JAK2V617F mutational status.

*

P< .05 versus controls.

†

P < .01 versus controls.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal